Relationship between complex stability and biokinetics of 99mTc-phosphate compounds

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Bone Scintigraphy

Background:

• Technetium-99m (99mTc) labeled phosphate compounds are widely used in bone imaging.
• The stability of these radiopharmaceuticals influences their efficacy in vivo.
• Understanding the relationship between complex stability and bone targeting is crucial for optimizing imaging agents.

Purpose of the Study:

• To determine the in vitro complex inertness of various 99mTc-phosphate compounds.
• To evaluate the in vivo biodistribution and bone imaging potential of these agents in rats.
• To elucidate the opposing roles of complex stability and bone affinity in 99mTc-phosphate bone imaging agents.

Main Methods:

• In vitro determination of complex inertness using protein binding assays after dilution in phosphate-buffered albumin.
• Evaluation of biodistribution in adult rats using commercially available kits for 99mTc-EHDP, -MDP, -PPi, and -TriP.
• Analysis of the relationship between complex stability and bone deposition.

Main Results:

• 99mTc-EHDP exhibited the highest in vitro complex stability.
• 99mTc-MDP demonstrated superior bone imaging performance in vivo, despite lower in vitro stability.
• Hydrolysis of the complex is necessary for separate deposition of phosphate and technetium in bone.

Conclusions:

• A balance between complex stability and bone affinity is essential for optimal 99mTc-phosphate bone imaging agents.
• 99mTc-MDP represents the best compromise among the investigated agents for bone scintigraphy at low ligand concentrations.
• The findings suggest that partial hydrolysis of the radiopharmaceutical is a key factor for effective bone targeting.